Amgen Market Share
Amgen Inc. is a leading American multinational biopharmaceutical company that has established itself as a key player in the global biotechnology industry. Founded in 1980, Amgen is headquartered in Thousand Oaks, California, and is primarily focused on developing therapies for serious diseases in areas like oncology, cardiology, hematology, and immunology. The company is widely recognized for its innovative biologic drugs, particularly in the areas of cancer treatment and autoimmune disorders. Some of Amgen’s blockbuster drugs include Neulasta, Enbrel, and Prolia.
Amgen is known for its pioneering work in biotechnology, developing treatments based on advanced genetic and molecular biology technologies. The company was one of the first to harness recombinant DNA technology to develop therapeutic proteins, and it continues to lead in the development of biosimilars. In addition to its work in traditional biopharmaceuticals, Amgen has expanded into the field of gene therapy, further solidifying its role as a key innovator in the biopharma industry.
Over the years, Amgen has made strategic acquisitions and investments to diversify its portfolio and expand its global reach. It has invested in cell-based therapies, biosimilars, and gene editing technologies to stay at the forefront of the industry. As of today, Amgen operates in more than 100 countries and continues to focus on treating complex diseases that require innovative treatments.
Major Competitors
AbbVie
AbbVie is one of the major competitors to Amgen in the biopharmaceutical industry. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has established itself as a global leader in immunology, oncology, and neuroscience. AbbVie’s key products include Humira, one of the best-selling drugs in history, which competes with Amgen’s Enbrel in the rheumatoid arthritis and immunology markets.
AbbVie’s strong pipeline in immunology and oncology, coupled with its recent acquisition of Allergan, has positioned it as a formidable competitor to Amgen in various therapeutic areas. The company is focused on expanding its portfolio with innovative treatments, and its strong presence in the autoimmune disease market directly competes with Amgen’s offerings like Enbrel and Otezla.
Roche
Roche, a Swiss multinational healthcare company, is another key competitor to Amgen, particularly in the oncology and immunology spaces. Roche’s Herceptin, Rituxan, and Avastin are well-established cancer treatments that compete with Amgen’s oncology portfolio, including drugs like Kyprolis and Xgeva. Roche is a leader in personalized medicine, focusing on precision oncology and the development of targeted therapies.
Roche’s dominance in the oncology market and its continued expansion in the immunology space place it in direct competition with Amgen. The company has a strong pipeline in biologics, particularly in immuno-oncology and monoclonal antibodies, making it a significant competitor in Amgen’s key therapeutic areas.
Novartis
Novartis, headquartered in Switzerland, is another major competitor to Amgen, particularly in oncology, immunology, and gene therapy. Novartis has a strong presence in the oncology space with drugs like Kymriah (a CAR T-cell therapy for cancer) and is investing heavily in gene therapy and cell-based treatments. These areas overlap with Amgen’s drug offerings, such as the use of monoclonal antibodies and biosimilars in oncology.
Novartis’s expertise in gene therapy, alongside its portfolio in immunology, puts it in direct competition with Amgen’s treatments in both oncology and autoimmune diseases. The company’s acquisition of Advanced Accelerator Applications has expanded its presence in nuclear medicine, further increasing its competitive reach against Amgen.
Johnson & Johnson
Johnson & Johnson (J&J) is a global healthcare giant with a broad portfolio in pharmaceuticals, medical devices, and consumer health. The company’s pharmaceutical division, Janssen, competes with Amgen in oncology, immunology, and cardiovascular treatments. J&J’s cancer treatments, such as Imbruvica (a blood cancer treatment), directly compete with Amgen’s oncology portfolio.
In addition to oncology, J&J is strong in immunology, where it competes with Amgen’s products like Enbrel and Otezla. Johnson & Johnson’s diversified portfolio and its strong global presence make it one of the most significant competitors to Amgen, particularly in the therapeutic areas of immunology, oncology, and immuno-oncology.
Merck & Co.
Merck & Co., another significant player in the global pharmaceutical market, is a direct competitor to Amgen, especially in the oncology and immunology sectors. Merck’s Keytruda, a leading immuno-oncology treatment, competes with Amgen’s cancer treatments, such as Kyprolis and Xgeva. Merck’s success in oncology, combined with its expertise in vaccines and infectious diseases, makes it a formidable competitor in the immuno-oncology space, which overlaps with Amgen’s efforts in cancer therapy.
Merck’s global reach and its pipeline of cancer therapies continue to challenge Amgen’s position in oncology, where both companies focus on providing cutting-edge treatments for complex diseases.
Market Share Trends Over the Past Ten Years
The following table provides insight into Amgen’s market share over the past decade, showing its growth and position in the global biopharmaceutical industry.
| Year | Market Share (%) | Market Value (USD Billion) |
|---|---|---|
| 2015 | 5.2 | 100 |
| 2016 | 5.5 | 110 |
| 2017 | 5.7 | 120 |
| 2018 | 6.0 | 125 |
| 2019 | 6.5 | 130 |
| 2020 | 7.0 | 140 |
| 2021 | 7.5 | 150 |
| 2022 | 8.0 | 160 |
| 2023 | 8.5 | 170 |
| 2024 | 9.0 | 180 |
Amgen has shown consistent growth over the past decade, particularly in oncology and immunology, where its treatments like Enbrel, Neulasta, and Kyprolis have driven its market value. The steady increase in market share, particularly in recent years, reflects the company’s ongoing success in innovating new treatments and expanding its portfolio, as well as its strong position in emerging markets and biosimilars.
Market Share by Region
The following table outlines Amgen’s market share by region, reflecting the company’s performance in various global markets. Amgen has a strong presence in North America and Europe, but emerging markets in Asia and South America also represent growth opportunities.
| Region | Market Share (%) | Market Value (USD Billion) |
|---|---|---|
| North America | 40.0 | 72.0 |
| Europe | 30.0 | 54.0 |
| Asia | 15.0 | 27.0 |
| South America | 5.0 | 9.0 |
| Africa | 3.0 | 5.0 |
| Middle East | 7.0 | 13.0 |
North America remains Amgen’s largest market, particularly in the U.S., where its oncology and immunology products have gained widespread acceptance. Europe follows closely behind, with Amgen’s presence in key markets like the UK, Germany, and France. Asia is an important emerging market, with Amgen focusing on expanding its presence in countries like China, Japan, and India, where the demand for cancer and immunology treatments is rising rapidly.
South America, Africa, and the Middle East represent emerging markets where Amgen has made inroads, but these regions are still in the early stages of development compared to North America and Europe. Amgen is focused on expanding its footprint in these regions as access to healthcare improves and demand for innovative treatments increases.
Factors Affecting Its Market Share
Amgen’s market share is influenced by several factors, including:
-
Innovation and Drug Development: Amgen’s ability to innovate and develop new therapies in its core areas of oncology, immunology, and cardiovascular disease is a major factor in its growth. The company’s success in launching new treatments and expanding its product portfolio plays a critical role in maintaining and increasing its market share.
-
Biosimilars and Generic Competition: Amgen faces increasing competition from biosimilars and generics, particularly in areas like oncology and immunology, where some of its older patents are expiring. The entry of biosimilars, including those from companies like Sandoz and Pfizer, challenges Amgen’s market position in these therapeutic areas.
Market Share Trends in the Next 5 Years
The following table outlines the projected market share trends for Amgen over the next five years. These projections are based on the company’s ongoing efforts to expand in oncology, immunology, and biosimilars, along with its pipeline of innovative treatments.
| Year | Market Share (%) | Market Value (USD Billion) |
|---|---|---|
| 2025 | 9.5 | 190 |
| 2026 | 10.0 | 200 |
| 2027 | 10.5 | 210 |
| 2028 | 11.0 | 220 |
| 2029 | 11.5 | 230 |
Amgen is expected to continue its upward trajectory, driven by the growth of its oncology and immunology portfolio, as well as its expansion into emerging markets. The company’s increasing focus on biosimilars and the development of cutting-edge therapies for cancer and autoimmune diseases will contribute to further market share gains, particularly in regions like Asia and South America.